» Articles » PMID: 38721478

Validity of Umbilical Cord Blood Procalcitonin in the Diagnosis of Early-Onset Neonatal Infection

Overview
Journal Cureus
Date 2024 May 9
PMID 38721478
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Early-onset neonatal infection (EONI) poses significant risks to neonatal health, necessitating reliable diagnostic markers for early detection. This study aims to evaluate the diagnostic validity of procalcitonin (PCT) concentration in umbilical cord blood as a biomarker for EONI.

Methods: This prospective study was conducted at Ho Chi Minh University Medical Center from April 2022 to September 2022. The PCT level was measured in umbilical cord blood at birth. Based on clinical, laboratory, and microbiologic results, neonates were classified into infected and non-infected groups.

Results: One hundred eighty neonates with risk factors for EONI were recruited. Among the neonates studied, 22 (12.2%) were classified as infected and 158 (87.8%) as non-infected by the classification criteria of clinical manifestations, laboratory tests, and blood culture. The median PCT in the infected group was significantly higher than that in the non-infected group (0.389 ng/mL vs. 0.127 ng/mL, p = 0.007). The optimal PCT cut-off was found by receiver operating characteristic (ROC) to be 0.23 ng/mL, with an area under the curve (AUC) of 0.87. The results were 59.1%, 98.7%, 86.2%, 94%, 45, and 0.41 for sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios, respectively. The post-test probability was 86% if the test was positive and 5% if it was negative.

Conclusion: Umbilical cord blood PCT might be a reliable marker in the diagnosis of EONI, and its value helps limit the harmful effects of unnecessary prescriptions in non-infected neonates. However, considering the low sensitivity of procalcitonin, further research is necessary to fully integrate this biomarker into clinical practice.

Citing Articles

The diagnostic accuracy of umbilical cord procalcitonin in predicting early-onset neonatal infection.

Nguyen T, Thi D, Truong Q, Pham T PLoS One. 2025; 20(1):e0316987.

PMID: 39821188 PMC: 11737792. DOI: 10.1371/journal.pone.0316987.


Neonatal Infectious Disease: A Major Contributor to Infant Mortality Requiring Advances in Point-of-Care Diagnosis.

Garvey M Antibiotics (Basel). 2024; 13(9).

PMID: 39335050 PMC: 11428345. DOI: 10.3390/antibiotics13090877.

References
1.
Haque K . Definitions of bloodstream infection in the newborn. Pediatr Crit Care Med. 2005; 6(3 Suppl):S45-9. DOI: 10.1097/01.PCC.0000161946.73305.0A. View

2.
van den Hoogen A, Gerards L, Verboon-Maciolek M, Fleer A, Krediet T . Long-term trends in the epidemiology of neonatal sepsis and antibiotic susceptibility of causative agents. Neonatology. 2009; 97(1):22-8. DOI: 10.1159/000226604. View

3.
Kuppala V, Meinzen-Derr J, Morrow A, Schibler K . Prolonged initial empirical antibiotic treatment is associated with adverse outcomes in premature infants. J Pediatr. 2011; 159(5):720-5. PMC: 3193552. DOI: 10.1016/j.jpeds.2011.05.033. View

4.
Su H, Chang S, Han C, Wu K, Li M, Huang C . Inflammatory markers in cord blood or maternal serum for early detection of neonatal sepsis-a systemic review and meta-analysis. J Perinatol. 2014; 34(4):268-74. DOI: 10.1038/jp.2013.186. View

5.
Chiesa C, Pellegrini G, Panero A, Osborn J, Signore F, Assumma M . C-reactive protein, interleukin-6, and procalcitonin in the immediate postnatal period: influence of illness severity, risk status, antenatal and perinatal complications, and infection. Clin Chem. 2003; 49(1):60-8. DOI: 10.1373/49.1.60. View